HealthInvest Partners AB Invests $2.39 Million in IQVIA Holdings Inc. (NYSE:IQV)

HealthInvest Partners AB acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,340 shares of the medical research company's stock, valued at approximately $2,392,000. IQVIA makes up 1.9% of HealthInvest Partners AB's investment portfolio, making the stock its 20th largest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. AdvisorNet Financial Inc boosted its position in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after purchasing an additional 95 shares during the period. BKM Wealth Management LLC purchased a new position in shares of IQVIA during the fourth quarter worth approximately $32,000. ST Germain D J Co. Inc. acquired a new position in shares of IQVIA in the 2nd quarter valued at $33,000. Activest Wealth Management purchased a new stake in IQVIA in the 4th quarter valued at $35,000. Finally, Live Oak Investment Partners acquired a new stake in IQVIA during the 4th quarter worth $41,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Guggenheim downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. Robert W. Baird upped their price objective on shares of IQVIA from $226.00 to $251.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They issued an "outperform" rating and a $290.00 target price on the stock. Evercore ISI raised their price objective on shares of IQVIA from $255.00 to $265.00 and gave the company a "market outperform" rating in a research report on Thursday, February 15th. Finally, UBS Group increased their target price on IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $256.80.

IQVIA Stock Performance

Shares of NYSE IQV traded down $1.96 during mid-day trading on Tuesday, hitting $229.20. The company had a trading volume of 920,953 shares, compared to its average volume of 977,335. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market cap of $41.60 billion, a price-to-earnings ratio of 31.68, a PEG ratio of 2.27 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The firm's 50 day simple moving average is $243.88 and its two-hundred day simple moving average is $221.10.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Insider Activity at IQVIA

In other news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the firm's stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,285 shares of company stock valued at $10,331,003. Corporate insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.